Showing results (51-60 of 103) with videos related to

Sort By:
Pageof 11
Cancer Research|July 5, 2014
Immediate utility of two approved agents to target both the metabolic mevalonate pathway and its restorative feedback loopAleksandra Pandyra, Peter J Mullen, Manpreet Kalkat, et al.
Blood Cancer Journal|September 11, 2024
Belantamab mafodotin, pomalidomide, and dexamethasone for triple class exposed/refractory relapsed multiple myeloma: a subgroup analysis of the ALGONQUIN trialArleigh McCurdy, Donna Reece, Martha L Louzada, et al.
Nature Medicine|January 4, 2024
Belantamab mafodotin, pomalidomide and dexamethasone in refractory multiple myeloma: a phase 1/2 trialSuzanne Trudel, Arleigh McCurdy, Martha L Louzada, et al.
Chemmedchem|May 28, 2011
Antagonism of the Stat3-Stat3 protein dimer with salicylic acid based small moleculesSteven Fletcher, Brent D G Page, Xialoei Zhang, et al.
Bioorganic & Medicinal Chemistry Letters|July 27, 2011
Identification of a non-phosphorylated, cell permeable, small molecule ligand for the Stat3 SH2 domainBrent D G Page, Steven Fletcher, Peibin Yue, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 3, 2011
Molecular target characterization and antimyeloma activity of the novel, insulin-like growth factor 1 receptor inhibitor, GTx-134Sheng-Ben Liang, Xiu-Zhi Yang, Young Trieu, et al.
Ejhaem|May 12, 2025
A Single-Center Study on Frontline Treatment for Multiple Myeloma Patients With 1q AbnormalitiesAshish Patel, Esther Masih-Khan, Adam Smith, et al.
Life Science Alliance|November 3, 2022
Myeloma immunoglobulin rearrangement and translocation detection through targeted capture sequencingSigny Chow, Olena Kis, David T Mulder, et al.
Leukemia & Lymphoma|June 2, 2020
An open-label, pharmacokinetic study of lenalidomide and dexamethasone therapy in previously untreated multiple myeloma (MM) patients with various degrees of renal impairment - validation of official dosing guidelinesChristine I Chen, Yanshuo Cao, Suzanne Trudel, et al.
Nature Communications|November 4, 2021
Longitudinal single-cell analysis of a myeloma mouse model identifies subclonal molecular programs associated with progressionDanielle C Croucher, Laura M Richards, Serges P Tsofack, et al.
Pageof 11